COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandalà M, Yamazaki N, Queirolo P, Guenzel C, Polli A, Thakur M, di Pietro A, Ascierto PA.
Schadendorf D, et al. Among authors: de groot jwb.
Eur J Cancer. 2024 Apr 24;204:114073. doi: 10.1016/j.ejca.2024.114073. Online ahead of print.
Eur J Cancer. 2024.
PMID: 38723373
Free article.